Trial Profile
A Randomized, Single-blind, Placebo-controlled, Parallel Group Study to Investigate the Effects of Intranasal RV568 (400microg) Administered Twice Daily to Adult Male Volunteers Experimentally Inoculated With Live Respiratory Syncytial Virus.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs RV 568 (Primary)
- Indications Respiratory syncytial virus infections; Respiratory tract infections
- Focus Therapeutic Use
- Sponsors RespiVert
- 09 Sep 2013 Results presented at the 23rd Annual Congress of the European Respiratory Society.
- 10 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 10 Nov 2010 New trial record